Feb 13, 2025 4:05pm EST OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
Jan 07, 2025 8:00am EST OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Nov 20, 2024 8:00am EST OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nov 07, 2024 4:05pm EST OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
Oct 29, 2024 4:05pm EDT OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
Oct 07, 2024 8:00am EDT ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Sep 25, 2024 8:30am EDT Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Sep 23, 2024 8:00am EDT OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Sep 16, 2024 7:30am EDT Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health